DOCSLIB.ORG

(En) Use of Blocking-Reagents for Reducing Unspecific T Cell-Activation Title

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(En) Use of Blocking-Reagents for Reducing Unspecific T Cell-Activation Title Title (en) Use of blocking-reagents for reducing unspecific T cell-activation Title (de) Verwendung von blockierenden Reagenzien zur Verringerung von unspezifischer T-Zellenaktivierung Title (fr) Utilisation de réactifs bloquants pour réduire l'activation de lymphocytes T non spécifiques Publication EP 3029067 A1 20160608 (EN) Application EP 14195645 A 20141201 Priority EP 14195645 A 20141201 Abstract (en) The present invention relates to a blocking-reagent for use in reducing unspecific T cell activation in T cell engaging therapies. The present invention further relates to pharmaceutical kit of parts and an in vitro method for evaluating unspecific T cell activation. IPC 8 full level C07K 16/24 (2006.01); A61K 39/395 (2006.01) CPC (source: EP US) A61K 35/17 (2013.01 - US); C07K 16/24 (2013.01 - EP); C07K 16/241 (2013.01 - US); C07K 16/2803 (2013.01 - US); C07K 16/2806 (2013.01 - US); C07K 16/2809 (2013.01 - US); C07K 16/2821 (2013.01 - US); C07K 16/2827 (2013.01 - US); C07K 16/2845 (2013.01 - US); C07K 16/2863 (2013.01 - US); C07K 16/2866 (2013.01 - US); C07K 16/2896 (2013.01 - US); C07K 16/3069 (2013.01 - US); G01N 33/56972 (2013.01 - US); A61K 2035/124 (2013.01 - US); C07K 2317/24 (2013.01 - US); C07K 2317/31 (2013.01 - US); C07K 2317/76 (2013.01 - EP US); C07K 2319/02 (2013.01 - US); G01N 2500/02 (2013.01 - US); G01N 2500/10 (2013.01 - US) Citation (applicant) • WO 2013092001 A1 20130627 - SYNIMMUNE GMBH [DE] • WO 9222653 A1 19921223 - GENENTECH INC [US] • US 5888508 A 19990330 - HILDRETH JAMES E [US] • US 5854070 A 19981229 - ROSE LYNN M [US] • EP 0057851 A2 19820818 - LEHMANN W MINOL HAUSTECH [DE] • WO 0170260 A1 20010927 - MILLENNIUM PHARM INC [US] • EP 2155783 B1 20130731 - AMGEN RES MUNICH GMBH [DE] • EP 2155788 B1 20120627 - MICROMET AG [DE] • WO 9954440 A1 19991028 - DOERKEN BERND [DE], et al • WO 2004106381 A1 20041209 - MICROMET AG [DE], et al • WO 2013092001 A1 20130627 - SYNIMMUNE GMBH [DE] • STAERZ UD; KANAGAWA 0; BEVAN MJ: "Hybrid antibodies can target sites for attack by T cells", NATURE, vol. 314, 1985, pages 628 - 631, XP008088110, DOI: doi:10.1038/314628a0 • PEREZ P; HOFFMAN RW; SHAW S; BLUESTONE JA; SEGAL DM: "Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody", NATURE, vol. 316, 1985, pages 354 - 356, XP001207655, DOI: doi:10.1038/316354a0 • JUNG G; HONSIK CJ; REISFELD RA; MÜLLER-EBERHARD HJ: "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target X anti-T3-conjugates", PROC NATL ACAD SCI USA, vol. 83, 1986, pages 4479 - 4483 • JUNG G; MÜLLER-EBERHARD HJ: "An in vitro model for tumor immunotherapy with antibody-heteroconjugates", IMMUNOL TODAY, vol. 9, 1988, pages 257 - 260, XP023938678, DOI: doi:10.1016/0167-5699(88)91304-7 • JUNG G; FREIMANN U; V.MARSCHALL Z; REISFELD RA; WILMANNS W: "Target cell induced T cell activation with bi- and trispecific antibody molecules", EUR J IMMUNOL, vol. 21, 1991, pages 2431 - 2435, XP000647636, DOI: doi:10.1002/eji.1830211020 • BARGOU R; LEO E; ZUGMAIER G ET AL.: "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", SCIENCE, vol. 321, 2008, pages 974 - 977 • ADAMS GP; WEINER LM: "Monoclonal antibody therapy of cancer", NAT BIOTECHNOL., vol. 23, 2005, pages 1147 - 57, XP002456710, DOI: doi:10.1038/nbt1137 • TOPP MS; KUFER P; GOKBUGET N ET AL.: "Targeted therapy with the T cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival", J CLIN ONCOL, vol. 29, 2011, pages 2493 - 2498, XP055112754, DOI: doi:10.1200/JCO.2010.32.7270 • KROESEN BJ; BUTER J; SLEIJFER DT ET AL.: "Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2", BR J CANCER, vol. 70, 1994, pages 652 - 661 • TIBBEN JG; BOERMAN OC; MASSUGER LF ET AL.: "Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab') in ovarian carcinoma patients", INT J CANCER, vol. 66, 1996, pages 477 - 483, XP001085380, DOI: doi:10.1002/(SICI)1097-0215(19960516)66:4<477::AID-IJC11>3.0.CO;2-5 • MAUS MV; GRUPP SA; PORTER DL; JUNE CH: "Antibody-modified T cells: CARs take the front seat for hematologic malignancies", BLOOD, vol. 123, 2014, pages 2625 - 35, XP055185132, DOI: doi:10.1182/blood-2013-11-492231 • MORGAN RA1; YANG JC; KITANO M; DUDLEY ME; LAURENCOT CM; ROSENBERG SA: "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2", MOL THER, vol. 18, no. 4, 2010, pages 843 - 851, XP055023624, DOI: doi:10.1038/mt.2010.24 • ROELAND LAMERISA; RENEE C.G. DE BRUINA; FAMKE L. SCHNEIDERSA; PAUL M.P.; VAN BERGEN EN HENEGOUWENB; HENK M.W. VERHEULA; TANJA D. D: "Bispecific antibody platforms for cancer immunotherapy", CRIT REV ONCOL HEMATOL., vol. S1040-84, no. 14, 20 August 2014 (2014-08-20), pages 00135 - 8 • KLINGER M; BRANDL C; ZUGMAIER G; HIJAZI Y; BARGOU RC; TOPP MS; GOKBUGET N; NEUMANN S; GOEBELER M; VIARDOT A: "Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3- bispecific BiTE antibody blinatumomab", BLOOD, vol. 119, 2012, pages 6226 - 33 • BRENTJENS RJ; DAVILA ML; RIVIERE , PARK J; WANG X; COWELL LG; BARTIDO S; STEFANSKI J; TAYLOR C; OLSZEWSKA M; BORQUEZ- OJEDA 0: "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia", SCI TRANSL MED, vol. 5, 2013, pages 1 - 9 • LEE DW; GARDNER R; PORTER DL; LOUIS CU; AHMED N; JENSEN M; GRUPP SA; MACKALL CL: "Current concepts in the diagnosis and management of cytokine release syndrome", BLOOD, vol. 124, no. 2, 10 July 2014 (2014-07-10), pages 188 - 95, XP055313556, DOI: doi:10.1182/ blood-2014-05-552729 • MOLEMA G; TERVAERT JW; KROESEN BJ; HELFRICH W; MEIJER DK; DE LEIJ LF: "CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro", BR J CANCER, vol. 82, 2000, pages 472 - 479, XP000944237, DOI: doi:10.1054/bjoc.1999.0945 • HOLT LJ1; HERRING C; JESPERS LS; WOOLVEN BP; TOMLINSON IM: "Domain antibodies: proteins for therapy", TRENDS BIOTECHNOL., vol. 21, no. 11, November 2003 (2003-11-01), pages 484 - 90, XP004467495, DOI: doi:10.1016/j.tibtech.2003.08.007 • III CR1; GONZALES JN; HOUTZ EK; LUDWIG JR; MELCHER ED; HALE JE; POURMAND R; KEIVENS VM; MYERS L; BEIDLER K: "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions", PROTEIN ENG, vol. 10, no. 8, August 1997 (1997-08-01), pages 949 - 57 • MARTIN F1; TONIATTI C; SALVATI AL; VENTURINI S; CILIBERTO G; CORTESE R; SOLLAZZO M: "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6", EMBO J., vol. 13, no. 22, 15 November 1994 (1994-11-15), pages 5303 - 9, XP002076260 • TRAUNECKER A; LANZAVECCHIA A; KARJALAINEN K: "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells", EMBO J., vol. 10, no. 12, December 1991 (1991-12-01), pages 3655 - 9, XP000232579 • TRAUNECKER A; LANZAVECCHIA A; KARJALAINEN K.: "Janusin: new molecular design for bispecific reagents", INT J CANCER SUPPL., vol. 7, 1992, pages 51 - 2, XP009171574 • SILVERMAN J1; LIU Q; BAKKER A; TO W; DUGUAY A; ALBA BM; SMITH R; RIVAS A; LI P; LE H: "Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains", NAT BIOTECHNOL., vol. 23, no. 12, 20 November 2005 (2005-11-20), pages 1556 - 61, XP009088629, DOI: doi:10.1038/nbt1166 • TAN SM: "The leucocyte fl2 (CD18) integrins: the structure, functional regulation and signalling properties", BIOSCI REP., vol. 32, no. 3, June 2012 (2012-06-01), pages 241 - 69 • EDWARD F. PLOW; THOMAS A. HAAS; LI ZHANG; JOSEPH LOFTUS; JEFFREY W. SMITH: "Ligand Binding to Integrins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 21 July 2000 (2000-07-21), pages 21785 - 21788 • SANCHEZ-MADRID F.; NAGY J.A.; ROBBINS E.; SIMON P.; SPRINGER T.: "The lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule", J. EXP. MED., vol. 158, 1983, pages 1785 - 1803, XP000606523, DOI: doi:10.1084/jem.158.6.1785 • BEATTY ET AL.: "J. Definition of a common leukocyte cell-surface antigen (Lp95-150) associated with diverse cell-mediated immune functions", J. IMMUNOL., vol. 131, 1983, pages 2913 - 2918 • ULBRICH H; ERIKSSON EE; LINDBOM L: "Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease", TRENDS PHARMACOL SCI, vol. 24, 2003, pages 640 - 647, XP004476617, DOI: doi:10.1016/j.tips.2003.10.004 • RUSNAK JM; KOPECKY SL; CLEMENTS IP; GIBBONS RJ; HOLLAND AE; PETERMAN HS; MARTIN JS; SAOUD JB; FELDMAN RL; BREISBLATT WM: "An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study", AM J CARDIOL, vol. 88, 2001, pages 482 - 487 • BOWEN JD; PETERSDORF SH; RICHARDS TL; MARAVILLA KR; DALE DC; PRICE TH; ST JOHN TP; YU AS: "Phase I study of a humanized anti- CD11/CD18 monoclonal antibody in multiple sclerosis", CLIN PHARMACOL THER, vol. 64, 1998, pages 339 - 346 • RHEE P; MORRIS J; DURHAM R; HAUSER C; CIPOLLE M; WILSON R; LUCHETTE F; MCSWAIN N; MILLER R: "Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group", J TRAUMA, vol. 49, 2000, pages 611 - 619 • BARAN KW; NGUYEN M; MCKENDALL GR; LAMBREW CT; DYKSTRA G; PALMERI ST; GIBBONS RJ; BORZAK S; SOBEL BE; GOURLAY SG: "Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study Group.
Load more

Recommended publications
  • Strategies and Challenges for the Next Generation of Therapeutic Antibodies
    FOCUS ON THERAPEUTIC ANTIBODIES PERSPECTIVES ‘validated targets’, either because prior anti- TIMELINE bodies have clearly shown proof of activity in humans (first-generation approved anti- Strategies and challenges for the bodies on the market for clinically validated targets) or because a vast literature exists next generation of therapeutic on the importance of these targets for the disease mechanism in both in vitro and in vivo pharmacological models (experi- antibodies mental validation; although this does not necessarily equate to clinical validation). Alain Beck, Thierry Wurch, Christian Bailly and Nathalie Corvaia Basically, the strategy consists of develop- ing new generations of antibodies specific Abstract | Antibodies and related products are the fastest growing class of for the same antigens but targeting other therapeutic agents. By analysing the regulatory approvals of IgG-based epitopes and/or triggering different mecha- biotherapeutic agents in the past 10 years, we can gain insights into the successful nisms of action (second- or third-generation strategies used by pharmaceutical companies so far to bring innovative drugs to antibodies, as discussed below) or even the market. Many challenges will have to be faced in the next decade to bring specific for the same epitopes but with only one improved property (‘me better’ antibod- more efficient and affordable antibody-based drugs to the clinic. Here, we ies). This validated approach has a high discuss strategies to select the best therapeutic antigen targets, to optimize the probability of success, but there are many structure of IgG antibodies and to design related or new structures with groups working on this class of target pro- additional functions.
    [Show full text]
  • WO 2014/152006 A2 25 September 2014 (25.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/152006 A2 25 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 39/395 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/026804 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 13 March 2014 (13.03.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/791,953 15 March 2013 (15.03.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: INTRINSIC LIFESCIENCES, LLC UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/US]; 505 Coast Boulevard South, Suite 408, La Jolla, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, California 92037 (US).
    [Show full text]
  • WO 2018/144999 Al 09 August 2018 (09.08.2018) W ! P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/144999 Al 09 August 2018 (09.08.2018) W ! P O PCT (51) International Patent Classification: Lennart; c/o Orionis Biosciences NV, Rijvisschestraat 120, A61K 38/00 (2006.01) C07K 14/555 (2006.01) Zwijnaarde, B-9052 (BE). TAVERNIER, Jan; c/o Orionis A61K 38/21 (2006.01) C12N 15/09 (2006.01) Biosciences NV, Rijvisschestraat 120, Zwijnaarde, B-9052 C07K 14/52 (2006.01) (BE). (21) International Application Number: (74) Agent: ALTIERI, Stephen, L. et al; Morgan, Lewis & PCT/US2018/016857 Bockius LLP, 1111 Pennsylvania Avenue, NW, Washing ton, D.C. 20004 (US). (22) International Filing Date: 05 February 2018 (05.02.2018) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/454,992 06 February 2017 (06.02.2017) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicants: ORIONIS BIOSCIENCES, INC. [US/US]; MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 275 Grove Street, Newton, MA 02466 (US).
    [Show full text]
  • EURL ECVAM Recommendation on Non-Animal-Derived Antibodies
    EURL ECVAM Recommendation on Non-Animal-Derived Antibodies EUR 30185 EN Joint Research Centre This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. EURL ECVAM Recommendations The aim of a EURL ECVAM Recommendation is to provide the views of the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) on the scientific validity of alternative test methods, to advise on possible applications and implications, and to suggest follow-up activities to promote alternative methods and address knowledge gaps. During the development of its Recommendation, EURL ECVAM typically mandates the EURL ECVAM Scientific Advisory Committee (ESAC) to carry out an independent scientific peer review which is communicated as an ESAC Opinion and Working Group report. In addition, EURL ECVAM consults with other Commission services, EURL ECVAM’s advisory body for Preliminary Assessment of Regulatory Relevance (PARERE), the EURL ECVAM Stakeholder Forum (ESTAF) and with partner organisations of the International Collaboration on Alternative Test Methods (ICATM). Contact information European Commission, Joint Research Centre (JRC), Chemical Safety and Alternative Methods Unit (F3) Address: via E.
    [Show full text]
  • Generation of Novel Intracellular Binding Reagents Based on the Human Γb-Crystallin Scaffold
    Generation of novel intracellular binding reagents based on the human γB-crystallin scaffold Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) vorgelegt der Naturwissenschaftlichen Fakultät I-Biowissenschaften der Martin-Luther-Universität Halle-Wittenberg Institut für Biochemie und Biotechnologie von Ewa Mirecka geboren am 17. Dezember 1976 in Gdynia, Polen Table of contents Table of contents 1. INTRODUCTION.........................................................................................................1 1.1 Monoclonal antibodies as a biomolecular scaffold..........................................................1 1.2 Binding molecules derived from non-immunoglobulin scaffolds.....................................3 1.2.1 Alternative protein scaffolds – general considerations............................................................ 3 1.2.2 Application of alternative binding molecules ........................................................................... 6 1.3 Affilin – novel binding molecules based on the human γB-crystallin scaffold................... 6 1.3.1 Human γB-crystallin as a molecular scaffold........................................................................... 6 1.3.2 Generation of a human γB-crystallin library and selection of first-generation Affilin molecules ................................................................................................................................ 8 1.4 Selection of binding proteins by phage display ...................................................................
    [Show full text]
  • University of Copenhagen, DK-2200 København N, Denmark * Correspondence: [email protected]; Tel.: +45-2988-1134 † These Authors Contributed Equally to This Work
    Toxin Neutralization Using Alternative Binding Proteins Jenkins, Timothy Patrick; Fryer, Thomas; Dehli, Rasmus Ibsen; Jürgensen, Jonas Arnold; Fuglsang-Madsen, Albert; Føns, Sofie; Laustsen, Andreas Hougaard Published in: Toxins DOI: 10.3390/toxins11010053 Publication date: 2019 Document version Publisher's PDF, also known as Version of record Citation for published version (APA): Jenkins, T. P., Fryer, T., Dehli, R. I., Jürgensen, J. A., Fuglsang-Madsen, A., Føns, S., & Laustsen, A. H. (2019). Toxin Neutralization Using Alternative Binding Proteins. Toxins, 11(1). https://doi.org/10.3390/toxins11010053 Download date: 09. apr.. 2020 toxins Review Toxin Neutralization Using Alternative Binding Proteins Timothy Patrick Jenkins 1,† , Thomas Fryer 2,† , Rasmus Ibsen Dehli 3, Jonas Arnold Jürgensen 3, Albert Fuglsang-Madsen 3,4, Sofie Føns 3 and Andreas Hougaard Laustsen 3,* 1 Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK; [email protected] 2 Department of Biochemistry, University of Cambridge, Cambridge CB3 0ES, UK; [email protected] 3 Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark; [email protected] (R.I.D.); [email protected] (J.A.J.); [email protected] (A.F.-M.); sofi[email protected] (S.F.) 4 Department of Biology, University of Copenhagen, DK-2200 København N, Denmark * Correspondence: [email protected]; Tel.: +45-2988-1134 † These authors contributed equally to this work. Received: 15 December 2018; Accepted: 12 January 2019; Published: 17 January 2019 Abstract: Animal toxins present a major threat to human health worldwide, predominantly through snakebite envenomings, which are responsible for over 100,000 deaths each year.
    [Show full text]
  • WO 2017/147538 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/147538 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/85 (2006.01) C12N 15/90 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/01953 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 24 February 2017 (24.02.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/300,387 26 February 2016 (26.02.2016) U S (84) Designated States (unless otherwise indicated, for every (71) Applicant: POSEIDA THERAPEUTICS, INC. kind of regional protection available): ARIPO (BW, GH, [US/US]; 4242 Campus Point Ct #700, San Diego, Califor GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, nia 92121 (US).
    [Show full text]
  • Novel Recombinant Traceable C-Met Antagonist-Avimer Antibody Mimetic Obtained by Bacterial Expression Analysis
    Original Article Novel Recombinant Traceable c-Met Antagonist-Avimer Antibody Mimetic Obtained by Bacterial Expression Analysis Bahram Baghban Kohnehrouz 1, Afsaneh Talischian 2, Alireza Dehnad 3, and Shahnoush Nayeri 4 1. Department of Plant Breeding & Biotechnology, University of Tabriz, Tabriz, Iran 2. Department of Biological Sciences, Higher Education Institute of Rab-Rashid, Tabriz, Iran 3. Department of Biotechnology, East Azerbaijan Research and Education Center Agricultural and Natural Resources, AREEO, Tabriz, Higher Education Institute of Rab-Rashid, Tabriz, Iran 4. Department of Biotechnology, Shahid Beheshti University, Tehran, Iran Abstract Background: Avimers are originally types of artificial proteins with multiple binding sites for specific binding to certain antigens. Various radioisotopes and nanoparticles link these molecules, which are widely used in early detection in tissue imaging, treat- ment and study on carcinogenesis. Among these, c-Met antagonist avimer (C426 avi- mer), with ability to bind the c-Met receptor of tyrosine kinase (RTK) is an attractive candidate for targeted cancer therapy. In this study, a novel traceable C426 avimer gene was designed and introduced by adding the 12nt tracer binding site encoded four specific amino acid residues at the C-terminal region of C426 avimer coding se- quence. Methods: The 282 bp DNA sequence encoded 94aa avimer protein was synthesized and sub-cloned into prokaryotic pET26b expression vector. The expression of the ma- ture peptide encoding the traceable avimer molecule was carried out in Escherichia coli strain BL21 using IPTG (Isopropyl β-D-1-thiogalactopyranoside) induction process. The expression level of the 11 kDa traceable avimer was studied by SDS-PAGE, west- * Corresponding author: Bahram Baghban Kohnehrouz, ern blot and ELISA analysis.
    [Show full text]
  • A Robust Pipeline for Rapid Production of Versatile Nanobody Repertoires
    ARTICLES A robust pipeline for rapid production of versatile nanobody repertoires Peter C Fridy1,8, Yinyin Li2,8, Sarah Keegan3, Mary K Thompson1, Ilona Nudelman1, Johannes F Scheid4, Marlene Oeffinger5,6, Michel C Nussenzweig4,7, David Fenyö3, Brian T Chait2 & Michael P Rout1 Nanobodies are single-domain antibodies derived from the any natural antibody8–12. Nanobodies are recombinant antigen- variable regions of Camelidae atypical immunoglobulins. They binding domains derived from these VHH regions. Unlike mono- show promise as high-affinity reagents for research, diagnostics clonal antibodies, they can readily be produced in large amounts and therapeutics owing to their high specificity, small size in bacterial expression systems9,13. Moreover, nanobodies (~15 kDa) and straightforward bacterial expression. However, are usually extremely stable, can bind antigens with affinities identification of repertoires with sufficiently high affinity has in the nanomolar range and are smaller in size (approximately proven time consuming and difficult, hampering nanobody 15 kDa) than other antibody constructs11,14–18. However, rapid implementation. Our approach generates large repertoires of and robust techniques for isolating extensive repertoires of high- readily expressible recombinant nanobodies with high affinities affinity nanobodies have proven elusive: the labor-intensiveness and specificities against a given antigen. We demonstrate and poor efficiency of current approaches are a major bottleneck the efficacy of this approach through the production of large for the widespread use of these reagents8,12,14, explaining why repertoires of nanobodies against two antigens, GFP and demand for nanobodies greatly exceeds supply8. mCherry, with Kd values into the subnanomolar range. After Here we present a highly optimized pipeline that allows the rapid mapping diverse epitopes on GFP, we were also able to design production of large repertoires of high-affinity nanobodies against ultrahigh-affinity dimeric nanobodies withK d values as low selected proteins.
    [Show full text]
  • Thesis + Long Intro
    Engineered discoidin domain from factor VIII binds αvβ3 integrin with antibody-like affinity Thesis by Gene Kym In Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy CALIFORNIA INSTITUTE OF TECHNOLOGY Pasadena, California 2014 (Defended April 23rd, 2014) ii © 2014 Gene Kym All Rights Reserved iii ACKNOWLEDGEMENTS I would like to thank my family for encouraging my studies and keeping me focused on long-term goals. I am thankful for the teachers who educated me, the mentors who trained me, my colleagues in student organizations who showed me the power of teamwork, and my friends for teaching me about the world outside the of academia. I am grateful to Steve, the Mayo Lab, and the individuals at Caltech who made my doctoral years a time of exploration, learning, and fun. iv ABSTRACT Alternative scaffolds are non-antibody proteins that can be engineered to bind new targets. They have found useful niches in the therapeutic space due to their smaller size and the ease with which they can be engineered to be bispecific. We sought a new scaffold that could be used for therapeutic ends and chose the C2 discoidin domain of factor VIII, which is well studied and of human origin. Using yeast surface display, we engineered the C2 domain to bind to αvβ3 integrin with a 16 nM affinity while retaining its thermal stability and monomeric nature. We obtained a crystal structure of the engineered domain at 2.1 Å resolution. We have christened this discoidin domain alternative scaffold the “discobody.” v TABLE OF CONTENTS Acknowledgements .......................................................................................................
    [Show full text]
  • WO 2015/037005 Al 19 March 2015 (19.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/037005 Al 19 March 2015 (19.03.2015) P O P C T (51) International Patent Classification: (74) Agents: AVERBUCH, Ariel et al; Dr.D.Graeser Ltd., 10 A61K 39/395 (2006.01) C07K 16/30 (2006.01) Zarhin St., Corex Building, 4366238 Raanana (IL). C07K 16/18 (2006.01) G01N 33/564 (2006.01) (81) Designated States (unless otherwise indicated, for every G01N 33/574 (2006.0 1) G01N 33/569 (2006.0 1) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/IL20 14/0508 14 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 11 September 2014 ( 11.09.2014) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (25) Filing Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (30) Priority Data: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 61/876,324 11 September 2013 ( 11.09.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: COMPUGEN LTD.
    [Show full text]
  • Efficient Selection of Darpins with Sub-Nanomolar Affinities Using SRP Phage Display
    doi:10.1016/j.jmb.2008.07.085 J. Mol. Biol. (2008) 382, 1211–1227 Available online at www.sciencedirect.com Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display Daniel Steiner, Patrik Forrer and Andreas Plückthun⁎ Department of Biochemistry, There is an ever-increasing demand to select specific, high-affinity binding University of Zürich, molecules against targets of biomedical interest. The success of such Winterthurerstrasse 190, selections depends strongly on the design and functional diversity of the 8057 Zürich, Switzerland library of binding molecules employed, and on the performance of the selection strategy. We recently developed SRP phage display that employs Received 13 May 2008; the cotranslational signal recognition particle (SRP) pathway for the received in revised form translocation of proteins to the periplasm. This system allows efficient 24 July 2008; filamentous phage display of highly stable and fast-folding proteins, such as accepted 30 July 2008 designed ankyrin repeat proteins (DARPins) that are virtually refractory to Available online conventional phage display employing the post-translational Sec pathway. 6 August 2008 DARPins comprise a novel class of binding molecules suitable to comple- ment or even replace antibodies in many biotechnological or biomedical applications. So far, all DARPins have been selected by ribosome display. Here, we harnessed SRP phage display to generate a phage DARPin library containing more than 1010 individual members. We were able to select well behaved and highly specific DARPins against a broad range of target proteins having affinities as low as 100 pM directly from this library, without affinity maturation. We describe efficient selection on the Fc domain of human IgG, TNFα, ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) as examples.
    [Show full text]